About The Author

Editorial & Columns

India–UK Free Trade Agreement-Data Exclusivity and Pharma Industry in India

May 15, 2025 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Small Country, Big Concern for the US: Ireland’s Pharma Exports

May 5, 2025 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Learning from the Longest Surviving Pharma Enterprise

April 28, 2025 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

China Plus One: India as a Fit Candidate in Pharmaceuticals

April 24, 2025 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Factoring Inflation in Medicine Prices: Need for a Sectoral Index in India

April 15, 2025 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

FY24 Review: Profitability of select Pharmaceutical Companies in India

April 9, 2025 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

FY25: Deciphering Pharma Exports from India

April 2, 2025 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Asset Swapping or Asset Trade in Pharmaceutical Industry

March 27, 2025 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Insider or an Outsider as a CEO: Insights on Pharmaceutical Industry in India

March 20, 2025 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

On the Right Side of Regulations: The USFDA and Indian Pharmaceutical Companies

March 12, 2025 | Dr. Anil Kumar Angrish | No Comments |

More